Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
This consultation sought comments from stakeholders on the European Commission's legislative proposals to strengthen and rationalise the EU pharmacovigilance systems. The Commission's proposals were published on 10 December 2008.
The outcome of this consultation and a list of responses are available below as download documents.
- STD Pharmaceutical
(24Kb) - Brunel Healthcare Manufacturing Ltd
(103Kb) - The Society and College of Radiographers
(444Kb) - National Patient Safety Agency
(47Kb) - The Herbal Forum
(36Kb) - Faculty of Pharmaceutical Medicine
(44Kb) - Bioindustry Association
(45Kb) - GE Healthcare
(12Kb) - Association of the British Pharmaceutical Industry
(176Kb) - UKCRC Registered Clinical Trials Unit
(10Kb) - Novartis Pharmaceuticals UK Ltd
(465Kb) - United Kingdom Clinical Pharmacy Association
(10Kb) - South Devon Healthcare NHS Foundation Trust
(12Kb) - Pharmaceutical Information and Pharmacovigilance Association
(38Kb) - HAI Europe, ISBD and MiEF
(355Kb) - Torbay Pharmacy Manufacturing Unit
(12Kb) - Fresenius Kabi
(10Kb) - Proprietary Association of Great Britain
(150Kb) - Glaxo SmithKline Services Unlimited
(92Kb)
Download documents:
-
Outcome of the Consultation on the European Commission’s Legislative Proposals to Strengthen Patient Safety (Pharmacovigilance) - MLX 359 (96Kb)
-
Public consultation (MLX 359): Consultation on the European Commission's legislative proposal to strengthen patient safety (‘pharmacovigilance’) (106Kb)
-
Impact Assessment of the European Commission's proposals to strengthen and rationalise the EU pharmacovigilance system (67Kb)
-
Public consultation (MLX 359): Consultation on the European Commission's legislative proposal to strengthen patient safety (‘pharmacovigilance’) - List of stakeholders (31Kb)

